- In March 2023, F. Hoffmann-La Roche Ltd partnered with Eli Lilly and Company to advance the development of Roche’s Elecsys Amyloid Plasma Panel (EAPP). This cutting-edge blood test is designed to enhance the early diagnosis of Alzheimer’s disease, offering potential improvements in patient outcomes. The collaboration highlights both companies' commitment to innovation in Alzheimer's detection and treatment
- In August 2022, AstraZeneca's Evusheld, a long-acting antibody combination comprising tixagevimab and cilgavimab (previously known as AZD7442), has been approved by Japan’s Ministry of Health, Labour and Welfare (MHLW). This therapy is indicated for both the prevention and treatment of symptomatic disease resulting from SARS-CoV-2 infection. The approval highlights AstraZeneca's ongoing efforts to provide effective therapeutic options in the fight against COVID-19
- In February 2022, Johnson & Johnson Services, Inc. received approval from the U.S. FDA for CARVYKTI, a groundbreaking CAR-T therapy specifically designed for the treatment of refractory multiple myeloma in adults. This innovative therapy offers new hope for patients who have not responded to prior treatments, showcasing advancements in personalized medicine for cancer care. The approval underscores Johnson & Johnson's commitment to developing effective solutions for complex hematological conditions
- In February 2021, Bristol Myers Squibb entered into a definitive agreement with The Rockefeller University, acquiring a worldwide exclusive license to develop, manufacture, and market a novel monoclonal antibody duo for COVID-19 therapy and prevention. This innovative treatment leverages two monoclonal antibodies designed to target and neutralize the SARS-CoV-2 virus by blocking its spike protein. The collaboration underscores Bristol Myers Squibb's commitment to advancing therapeutic solutions against COVID-19 through cutting-edge antibody technology
- In February 2021, AbbVie formed a partnership with Caribou Biosciences, Inc. by entering into a license agreement focused on the research and development of chimeric antigen receptor (CAR) T cell therapeutics. This collaboration aims to leverage Caribou’s innovative gene-editing technology to enhance the efficacy and safety of CAR T cell therapies for cancer treatment. The agreement reflects both companies' commitment to advancing groundbreaking therapeutic approaches in the field of immuno-oncology
Frequently Asked Questions
The market is segmented based on Segmentation, By Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormone, Vaccines, Synthetic Immunomodulatory, and Other), Service (Laboratory Testing, Custom Testing / Customer Proprietary Testing, Compendial, and Multi Compendial Laboratory Testing), Raw Material Type (Formulation Excipients, Active Pharmaceutical Ingredients (API), and Compendial Methods (USP / EP / JP) Based Vendor Qualification Program Support), Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, Cardiovascular Diseases, Neurological Diseases, and Other) – Industry Trends and Forecast to 2031
.
The Global Biopharmaceuticals Market size was valued at USD 1.02 USD Billion in 2023.
The Global Biopharmaceuticals Market is projected to grow at a CAGR of 6% during the forecast period of 2024 to 2031.
The major players operating in the market include Amgen , Lilly, Johnson & Johnson Private Limited, Sanofi, Abbott, AstraZeneca, F. Hoffmann-La Roche , bioMérieux, Novartis AG, Bristol-Myers Squibb Company, Novo Nordisk A/S, Merck & Co. , GlaxoSmithKline Plc, Biogen, Bayer AG, Pfizer -.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
